Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer

Hiroyuki Hamakawa, Koh Ichi Nakashiro, Tomoki Sumida, Satoru Shintani, Jeffrey N. Myers, Robert P. Takes, Alessandra Rinaldo, Alfio Ferlit

Research output: Contribution to journalReview article

57 Citations (Scopus)

Abstract

Background. Recently, attention has been focused on molecular targeted cancer therapy in various tumors. Although there is no single consistent molecular target specific for oral squamous cell carcinoma (OSCC) and salivary gland cancer (SGC), there are a number of promising candidate proteins. The aim of this review is to introduce the basic evidences to support the molecular targeting for OSCC and SGC. Methods. We focused on the 4 molecules, epidermal growth factor receptor (EGFR), cyclooxygenase-2 (COX-2), peroxisome proliferator-activated receptor γ (PPARγ), and progesterone receptor, that are, respectively, associated with the proliferation and the differentiation of OSCC and SGC. Results. Gefitinib ("Iressa," ZD1839), a small molecule EGFR tyrosine kinase inhibitor, can inhibit the proliferation of OSCC cell lines in a dose- and time-dependent manner and lead to cell cycle arrest with accumulation of cells in the G1 phase, and a decrease of cells in S phase. The agent suppressed tumor metastasis in the animal model. Furthermore, a cooperative antiproliferative effect was obtained when cancer cells were treated with radiation followed by gefitinib. While radiation alone did not significantly affect p38 mitogen-activated protein kinase and MAP kinase kinase (MEK)1/2 autophospho-rylation, the combination of gefitinib and radiation completely inhibited the downstream signaling of EGFR. Gefitinib enhanced tumor radioresponsiveness by multiple mechanisms, including the growth inhibition and effects on DNA repair after exposure to radiation. Next, the level of COX-2 expression correlated inversely with increased tumor radiation sensitivity. Treatment with celecoxib, a COX-2 selective inhibitor, enhanced the radioresponsiveness of HSC-2 cells, which constitutively expressed COX-2. Another promising molecular target is the PPARγ, which is a member of the nuclear receptor superfamily of ligand-acti-vated transcription factors. Recent studies have demonstrated that PPARγ ligands induce cellular differentiation and inhibit cell growth in carcinomas of various types. These data suggest that synthetic PPARγ ligands may be useful for molecular targeting of oral cancer. Finally, the possibility of using molecular targeted therapy directed at hormone receptors in the treatment of advanced SGCs was described. Conclusion. The basic data strongly suggested the possibility of tumor suppression by targeting these molecules. Studies of different targeted agents alone or with more conventional treatment modalities are needed to fully determine what role the targeted therapy will play in the management of patients with OSCC and SGC.

Original languageEnglish
Pages (from-to)800-809
Number of pages10
JournalHead and Neck
Volume30
Issue number6
DOIs
Publication statusPublished - Jun 1 2008
Externally publishedYes

Fingerprint

Salivary Gland Neoplasms
Molecular Targeted Therapy
Mouth Neoplasms
Peroxisome Proliferator-Activated Receptors
Squamous Cell Carcinoma
MAP Kinase Kinase Kinase 1
Cyclooxygenase 2
Epidermal Growth Factor Receptor
Neoplasms
Celecoxib
Radiation
Ligands
MAP Kinase Kinase Kinase 2
Play Therapy
Cyclooxygenase 2 Inhibitors
Radiation Tolerance
G1 Phase
p38 Mitogen-Activated Protein Kinases
Progesterone Receptors
Cytoplasmic and Nuclear Receptors

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

Hamakawa, H., Nakashiro, K. I., Sumida, T., Shintani, S., Myers, J. N., Takes, R. P., ... Ferlit, A. (2008). Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head and Neck, 30(6), 800-809. https://doi.org/10.1002/hed.20830

Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. / Hamakawa, Hiroyuki; Nakashiro, Koh Ichi; Sumida, Tomoki; Shintani, Satoru; Myers, Jeffrey N.; Takes, Robert P.; Rinaldo, Alessandra; Ferlit, Alfio.

In: Head and Neck, Vol. 30, No. 6, 01.06.2008, p. 800-809.

Research output: Contribution to journalReview article

Hamakawa, H, Nakashiro, KI, Sumida, T, Shintani, S, Myers, JN, Takes, RP, Rinaldo, A & Ferlit, A 2008, 'Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer', Head and Neck, vol. 30, no. 6, pp. 800-809. https://doi.org/10.1002/hed.20830
Hamakawa, Hiroyuki ; Nakashiro, Koh Ichi ; Sumida, Tomoki ; Shintani, Satoru ; Myers, Jeffrey N. ; Takes, Robert P. ; Rinaldo, Alessandra ; Ferlit, Alfio. / Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. In: Head and Neck. 2008 ; Vol. 30, No. 6. pp. 800-809.
@article{5fc7a2be2741440996a6ad15e60a194c,
title = "Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer",
abstract = "Background. Recently, attention has been focused on molecular targeted cancer therapy in various tumors. Although there is no single consistent molecular target specific for oral squamous cell carcinoma (OSCC) and salivary gland cancer (SGC), there are a number of promising candidate proteins. The aim of this review is to introduce the basic evidences to support the molecular targeting for OSCC and SGC. Methods. We focused on the 4 molecules, epidermal growth factor receptor (EGFR), cyclooxygenase-2 (COX-2), peroxisome proliferator-activated receptor γ (PPARγ), and progesterone receptor, that are, respectively, associated with the proliferation and the differentiation of OSCC and SGC. Results. Gefitinib ({"}Iressa,{"} ZD1839), a small molecule EGFR tyrosine kinase inhibitor, can inhibit the proliferation of OSCC cell lines in a dose- and time-dependent manner and lead to cell cycle arrest with accumulation of cells in the G1 phase, and a decrease of cells in S phase. The agent suppressed tumor metastasis in the animal model. Furthermore, a cooperative antiproliferative effect was obtained when cancer cells were treated with radiation followed by gefitinib. While radiation alone did not significantly affect p38 mitogen-activated protein kinase and MAP kinase kinase (MEK)1/2 autophospho-rylation, the combination of gefitinib and radiation completely inhibited the downstream signaling of EGFR. Gefitinib enhanced tumor radioresponsiveness by multiple mechanisms, including the growth inhibition and effects on DNA repair after exposure to radiation. Next, the level of COX-2 expression correlated inversely with increased tumor radiation sensitivity. Treatment with celecoxib, a COX-2 selective inhibitor, enhanced the radioresponsiveness of HSC-2 cells, which constitutively expressed COX-2. Another promising molecular target is the PPARγ, which is a member of the nuclear receptor superfamily of ligand-acti-vated transcription factors. Recent studies have demonstrated that PPARγ ligands induce cellular differentiation and inhibit cell growth in carcinomas of various types. These data suggest that synthetic PPARγ ligands may be useful for molecular targeting of oral cancer. Finally, the possibility of using molecular targeted therapy directed at hormone receptors in the treatment of advanced SGCs was described. Conclusion. The basic data strongly suggested the possibility of tumor suppression by targeting these molecules. Studies of different targeted agents alone or with more conventional treatment modalities are needed to fully determine what role the targeted therapy will play in the management of patients with OSCC and SGC.",
author = "Hiroyuki Hamakawa and Nakashiro, {Koh Ichi} and Tomoki Sumida and Satoru Shintani and Myers, {Jeffrey N.} and Takes, {Robert P.} and Alessandra Rinaldo and Alfio Ferlit",
year = "2008",
month = "6",
day = "1",
doi = "10.1002/hed.20830",
language = "English",
volume = "30",
pages = "800--809",
journal = "Head and Neck Surgery",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer

AU - Hamakawa, Hiroyuki

AU - Nakashiro, Koh Ichi

AU - Sumida, Tomoki

AU - Shintani, Satoru

AU - Myers, Jeffrey N.

AU - Takes, Robert P.

AU - Rinaldo, Alessandra

AU - Ferlit, Alfio

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Background. Recently, attention has been focused on molecular targeted cancer therapy in various tumors. Although there is no single consistent molecular target specific for oral squamous cell carcinoma (OSCC) and salivary gland cancer (SGC), there are a number of promising candidate proteins. The aim of this review is to introduce the basic evidences to support the molecular targeting for OSCC and SGC. Methods. We focused on the 4 molecules, epidermal growth factor receptor (EGFR), cyclooxygenase-2 (COX-2), peroxisome proliferator-activated receptor γ (PPARγ), and progesterone receptor, that are, respectively, associated with the proliferation and the differentiation of OSCC and SGC. Results. Gefitinib ("Iressa," ZD1839), a small molecule EGFR tyrosine kinase inhibitor, can inhibit the proliferation of OSCC cell lines in a dose- and time-dependent manner and lead to cell cycle arrest with accumulation of cells in the G1 phase, and a decrease of cells in S phase. The agent suppressed tumor metastasis in the animal model. Furthermore, a cooperative antiproliferative effect was obtained when cancer cells were treated with radiation followed by gefitinib. While radiation alone did not significantly affect p38 mitogen-activated protein kinase and MAP kinase kinase (MEK)1/2 autophospho-rylation, the combination of gefitinib and radiation completely inhibited the downstream signaling of EGFR. Gefitinib enhanced tumor radioresponsiveness by multiple mechanisms, including the growth inhibition and effects on DNA repair after exposure to radiation. Next, the level of COX-2 expression correlated inversely with increased tumor radiation sensitivity. Treatment with celecoxib, a COX-2 selective inhibitor, enhanced the radioresponsiveness of HSC-2 cells, which constitutively expressed COX-2. Another promising molecular target is the PPARγ, which is a member of the nuclear receptor superfamily of ligand-acti-vated transcription factors. Recent studies have demonstrated that PPARγ ligands induce cellular differentiation and inhibit cell growth in carcinomas of various types. These data suggest that synthetic PPARγ ligands may be useful for molecular targeting of oral cancer. Finally, the possibility of using molecular targeted therapy directed at hormone receptors in the treatment of advanced SGCs was described. Conclusion. The basic data strongly suggested the possibility of tumor suppression by targeting these molecules. Studies of different targeted agents alone or with more conventional treatment modalities are needed to fully determine what role the targeted therapy will play in the management of patients with OSCC and SGC.

AB - Background. Recently, attention has been focused on molecular targeted cancer therapy in various tumors. Although there is no single consistent molecular target specific for oral squamous cell carcinoma (OSCC) and salivary gland cancer (SGC), there are a number of promising candidate proteins. The aim of this review is to introduce the basic evidences to support the molecular targeting for OSCC and SGC. Methods. We focused on the 4 molecules, epidermal growth factor receptor (EGFR), cyclooxygenase-2 (COX-2), peroxisome proliferator-activated receptor γ (PPARγ), and progesterone receptor, that are, respectively, associated with the proliferation and the differentiation of OSCC and SGC. Results. Gefitinib ("Iressa," ZD1839), a small molecule EGFR tyrosine kinase inhibitor, can inhibit the proliferation of OSCC cell lines in a dose- and time-dependent manner and lead to cell cycle arrest with accumulation of cells in the G1 phase, and a decrease of cells in S phase. The agent suppressed tumor metastasis in the animal model. Furthermore, a cooperative antiproliferative effect was obtained when cancer cells were treated with radiation followed by gefitinib. While radiation alone did not significantly affect p38 mitogen-activated protein kinase and MAP kinase kinase (MEK)1/2 autophospho-rylation, the combination of gefitinib and radiation completely inhibited the downstream signaling of EGFR. Gefitinib enhanced tumor radioresponsiveness by multiple mechanisms, including the growth inhibition and effects on DNA repair after exposure to radiation. Next, the level of COX-2 expression correlated inversely with increased tumor radiation sensitivity. Treatment with celecoxib, a COX-2 selective inhibitor, enhanced the radioresponsiveness of HSC-2 cells, which constitutively expressed COX-2. Another promising molecular target is the PPARγ, which is a member of the nuclear receptor superfamily of ligand-acti-vated transcription factors. Recent studies have demonstrated that PPARγ ligands induce cellular differentiation and inhibit cell growth in carcinomas of various types. These data suggest that synthetic PPARγ ligands may be useful for molecular targeting of oral cancer. Finally, the possibility of using molecular targeted therapy directed at hormone receptors in the treatment of advanced SGCs was described. Conclusion. The basic data strongly suggested the possibility of tumor suppression by targeting these molecules. Studies of different targeted agents alone or with more conventional treatment modalities are needed to fully determine what role the targeted therapy will play in the management of patients with OSCC and SGC.

UR - http://www.scopus.com/inward/record.url?scp=46249097974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46249097974&partnerID=8YFLogxK

U2 - 10.1002/hed.20830

DO - 10.1002/hed.20830

M3 - Review article

C2 - 18429007

AN - SCOPUS:46249097974

VL - 30

SP - 800

EP - 809

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 1043-3074

IS - 6

ER -